Nab-P+Cb+PD1 Inhibitors Combined/not Combined with Bevacizumab As Neoadjuvant Therapy for Early TNBC

"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group A： Albumin-bound paclitaxe (260 mg/m²,d 1)+Carboplatin (AUC=5, d 1)+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"

"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group B: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15)+Carboplatin (AUC=5, d 1 )+Camrelizumab (200 mg, d 1), 21 days as one cycle, 6 cycles;"

"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group C： Albumin-bound paclitaxe (260 mg/m²,d 1, 6 cycles)+Carboplatin (AUC=5,d 1, 6 cycles)+Camrelizumab (200 mg, , d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"

"This study is a single center, non blinded, randomized phase II clinical trial. A total of 64 TNBC patients are planned to be enrolled. Patients who meet the inclusion criteria will be randomly divided into four groups at a ratio of 1:1:1:1 and stratified according to T stage and N stage.~Group D: Albumin-bound paclitaxe (125 mg/m²,d 1,8,15,6 cycles)+Carboplatin (AUC=5, d 1, 6 cycles)+Camrelizumab (200 mg, d 1, 6 cycles)+Bevacizumab (15mg/kg, d 1,5 cycles), 21 days as one cycle;"